Compass Minerals International, Inc., provides essential minerals in the United States, Canada, the United Kingdom, and internationally. It operates through two segments, Salt and Plant Nutrition. The Salt segment produces, markets, and sells sodium chloride and magnesium chloride, including rock salt, mechanically and solar evaporated salt, and brine and flake magnesium chloride products; and purchases potassium chloride and calcium chloride to sell as finished products or to blend with sodium chloride to produce specialty products. This segment provides products for use as a deicer for roadways, consumer, and professional use; as an ingredient in chemical production; for water treatment, human, and animal nutrition; and for various other consumer and industrial uses, as well as records management services. The Plant Nutrition segment produces sulfate of potash specialty fertilizers in various grades that are used in broadcast spreaders, direct application, and liquid fertilizer solutions under the Protassium+ brand name; turf products used by the turf and ornamental markets, as well as for blends used on golf course greens; organic products; and develops and produces a portfolio of magnesium chloride-based aerial and ground fire retardant products. This segment provides its products to distributors and retailers of crop inputs, as well as growers. The company was formerly known as Salt Holdings Corporation and changed its name to Compass Minerals International, Inc. in December 2003. Compass Minerals International, Inc. was founded in 1844 and is headquartered in Overland Park, Kansas.

Compass Minerals Intl Inc

The latest announcement is out from Cimpress ( ($CMPR) ). On May 11, 2026, Cimpress plc agreed to acquire CEWE’s commercial online print businesses...

Cimpress to Acquire CEWE’s Commercial Online Print Units

In a report released on May 8, Kai Klose from Berenberg Bank maintained a Buy rating on Eurocommercial Properties NV, with a price target of €32.00...

Berenberg Bank Reaffirms Their Buy Rating on Eurocommercial Properties NV (ECMPA)

Kepler Capital analyst Benjamin Legrand maintained a Buy rating on Eurocommercial Properties NV on May 8 and set a price target of €30.00. The comp...

Kepler Capital  Sticks to Their Buy Rating for Eurocommercial Properties NV (ECMPA)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dianthus Therapeutics (DNTH), Tenax Therapeutics (TE...

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Tenax Therapeutics (TENX) and Compass Therapeutics (CMPX)

Analysts are intrested in these 5 stocks: ( ($EXE) ), ( ($IP) ), ( ($ESPR) ), ( ($CMPS) ) and ( ($TNXP) ). Here is a breakdown of their recent


EXE, IP, ESPR, CMPS, TNXP Trending With Analysts

Eurocommercial Properties NV ( ($NL:ECMPA) ) has issued an announcement. Eurocommercial Properties reported a solid start to 2026, highlighted by t...

Eurocommercial lifts sales and income as new Swedish mall boosts portfolio

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GoodRx Holdings (GDRX), Compass Therapeutics (CMPX) ...

Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (GDRX), Compass Therapeutics (CMPX) and Addus Homecare (ADUS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Compass Therapeutics (CMPX) and Aktis Oncology, Inc....

Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Industrial Goods sector as 3 analysts just weighed in on Caterpillar (CAT), Cimpress (CMPR) and Builder...

Analysts Are Bullish on These Industrial Goods Stocks: Caterpillar (CAT), Cimpress (CMPR)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Indivior (INDV), Aclaris Therapeutics (ACRS) and Com...

Analysts Are Bullish on Top Healthcare Stocks: Indivior (INDV), Aclaris Therapeutics (ACRS)

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Compass Therapeutics, with a price target of $6.00. Accordi...

LifeSci Capital Sticks to Its Buy Rating for Compass Therapeutics (CMPX)

In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on COMPASS Pathways, with a price target of $23.00. Acc...

LifeSci Capital Sticks to Its Buy Rating for COMPASS Pathways (CMPS)

Central Mine Planning & Design Institute Limited ( ($IN:CMPDI) ) has provided an update. Central Mine Planning & Design Institute Limited reported ...

CMPDI Beats Exploration Targets, Renews MECL Pact and Backs Rare Earths Block

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Compass Therapeutics (CMPX), Grace Therapeutics (GRC...

Analysts Offer Insights on Healthcare Companies: Compass Therapeutics (CMPX), Grace Therapeutics (GRCE) and Simulations Plus (SLP)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS) and Nuvalent (NUVL) with bul...

Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS) and Nuvalent (NUVL)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on COMPASS Pathways today and set a price target of $70.00. Trucchio covers the He...

H.C. Wainwright Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)

Psychedelic and neuroactive-compound biotech stocks are soaring on Monday, April 20, 2026, after a major White House executive order signaled stron...

PBM, CMPS, ATAI: Psychedelic Biotech Stocks Soar after White House Order for Faster FDA Reviews

Eurocommercial Properties NV ( ($NL:ECMPA) ) just unveiled an announcement. Eurocommercial Properties has completed the €110 million acquisition of...

Market Cap	$795.84M	P/E Ratio	32.88
52W High	$30.04	52W Low	$16.40
Div Yield	N/A	Payout Ratio	0.0%
EPS Growth 3Y	-37.2%	52W Position	94.3%
Overall Score	63	Value Score	60
Quality Score	39	Technical Score	90

EPS Current Est	$0.89	EPS Next Est	$1.11
EPS Growth Est	+24.7%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	CMP	$29.26	+4.76%	1.59M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	CMP	$29.26	+4.8%	1.59M
3
4
5
6

CMP

CMP

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Compass Minerals Intl Inc Data in Excel

Get Compass Minerals Intl Inc Data in Excel